Study of a new drug with sacituzumab tirumotecan for solid tumors
Part of Cancer clinical trials.
This trial tests a new investigational drug (MK-2010) combined with sacituzumab tirumotecan (Sac-TMT) for people with various solid tumors. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to carry out daily activities with little or no help (ECOG 0 or 1).
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- If you have HIV, it must be well-controlled with antiretroviral therapy.
- If you have hepatitis B or C, your viral load must be undetectable.
- You have not had cancer treatment (like chemotherapy or immunotherapy) in the last 4 weeks.
- You are not currently taking blood thinners (anticoagulants).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This study tests a new combination of drugs (sacituzumab tirumotecan plus others) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination works better for those who have not had treatment before or whose cancer progressed after one line of therapy.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.